September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Mi­rador Ther­a­peu­tics: Ap­ply­ing pre­ci­sion med­i­cine to im­mune dis­ease

Ryan Cross

Senior Science Correspondent

↑
  • CEO Mark McKen­na
  • To­tal raised $400 mil­lion
  • Head­quar­ters San Diego, CA

2024 is on track to be a record-break­ing year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­vo and Vi­a­tris set­tle Ozem­pic patent suit as gener­ic en­try date re­mains un­known

Spe­cial re­port 2024: Meet 20 women break­ing new ground in bio­phar­ma R&D

Post-Hoc: What does an ac­tivist want with Pfiz­er?

Pfiz­er tar­get­ed by ac­tivist, fol­low­ing post-pan­dem­ic stum­bles — re­ports

As­traZeneca makes an­oth­er car­dio deal, bet­ting $100M on Chi­na com­pa­ny’s lipid drug

Ju­do Bio launch­es with $100M for kid­ney-tar­get­ed siR­NA ther­a­pies

A service from the Financial Times